{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T15:40:12Z","timestamp":1715355612356},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.arbres.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T17:58:16Z","timestamp":1698688696000},"page":"129-130","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystic Fibrosis: From Salty Malediction to Possible Cure"],"prefix":"10.1016","volume":"60","author":[{"given":"Amparo","family":"Sole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane C.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Quintana-Gallego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2023.10.007_bib0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2023.10.007_bib0090","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2023.10.007_bib0095","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2023.10.007_bib0100","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: interim results of an open-label phase 3 clinical trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2023.10.007_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2023.10.007_bib0110","doi-asserted-by":"crossref","first-page":"1158207","DOI":"10.3389\/fphar.2023.1158207","article-title":"Post-approval studies with the CFTR modulators elexacaftor\u2013tezacaftor\u2013ivacaftor","volume":"14","author":"Tummler","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.arbres.2023.10.007_bib0115","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.arbres.2023.05.017","article-title":"Experience with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced disease","volume":"59","author":"Carrasco Hern\u00e1ndez","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.10.007_bib0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ppul.23337","article-title":"Mortality from cystic fibrosis in Europe: 1994\u20132010","volume":"51","author":"Quintana-Gallego","year":"2016","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.arbres.2023.10.007_bib0125","unstructured":"ECFSPR Annual Report 2021. Denmark: European Cystic Fibrosis Society; 2023."},{"key":"10.1016\/j.arbres.2023.10.007_bib0130","unstructured":"2022 Cystic Fibrosis Foundation Patient Registry Highlights. Bethesda, Maryland: Cystic Fibrosis Foundation; 2023."},{"key":"10.1016\/j.arbres.2023.10.007_bib0135","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jcf.2022.01.006","article-title":"The lung microbiota in children with cystic fibrosis captured by induced sputum sampling","volume":"21","author":"Weiser","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.arbres.2023.10.007_bib0140","doi-asserted-by":"crossref","first-page":"2000006","DOI":"10.1183\/13993003.00006-2020","article-title":"An observational study of the lung clearance index throughout childhood in cystic fibrosis: early years matter","volume":"56","author":"Davies","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2023.10.007_bib0145","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/thoraxjnl-2020-216085","article-title":"Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis","volume":"76","author":"Bayfield","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2023.10.007_bib0150","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.arbres.2023.10.007_bib0155","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1016\/S1569-1993(23)00467-8","article-title":"P092 Preliminary observations of treatment and symptom reporting in the Home-Reported Outcomes in cystic fibrosis study (HERO-2)","volume":"22","author":"Brown","year":"2023","journal-title":"J Cystic Fibros"},{"key":"10.1016\/j.arbres.2023.10.007_bib0160","doi-asserted-by":"crossref","first-page":"2300110","DOI":"10.1183\/13993003.00110-2023","article-title":"Theratyping cystic fibrosis patients to guide elexacaftor\/tezacaftor\/ivacaftor out-of-label prescription","volume":"62","author":"Dreano","year":"2023","journal-title":"Eur Respir J"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289623003599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289623003599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T14:59:13Z","timestamp":1715353153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289623003599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0300289623003599"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2023.10.007","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic Fibrosis: From Salty Malediction to Possible Cure","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}